https://omg10.com/4/10736335
As cell-based therapies become more complex and manufacturing networks expand, resilience can no longer be an afterthought and cryopreservation can no longer simply be a step that is validated during development and left alone. It must play an ongoing role in product consistency, potency, and reliability.
The post Frozen Doesn’t Mean Stable: Rethinking Cryopreservation in Cell and Gene Therapy Manufacturing appeared first on MedCity News.
